With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.

UVM Medical Center is the only Vermont hospital offering Tricuspid Transcatheter Edge-to-Edge Repair (TEER) This new heart ...

With growth in percutaneous fixes for the valve, surgeons at STS 2025 called for innovation, team-based care, and more data.

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

The U.S. national coverage analysis for transcatheter tricuspid valve replacement drew support from cardiologists and device makers alike, but the Medical Device Manufacturers Association is urging ...

As tools become more precise and non-invasive, doctors are able to diagnose and treat heart conditions with greater accuracy and efficiency.

The Heart Valve Devices Market is driven by advancements in aortic, mitral, tricuspid, and pulmonary valve technologies. It includes biological and m ...

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS is $0.59, expectations were $0.551. Mark Wilterding: [Starts Abruptly] ...